The two companies have been working together since 2017, with Takeda pledging $100 million to help GammaDelta advance its cell therapy platform as part of a "build-to-buy" arrangement. The ...
Takeda has chalked up another milestone for its Alofisel cell therapy for a complication of Crohn's disease, becoming the first allogeneic stem cell therapy to be approved in Japan.
Takeda paid Protagonist $300 million one year ago to license rights to rusfertide, which the companies are developing to ...
GlobalData on MSN8d
Takeda broadens its deal with BridGene for up to $770mTakeda will pay $46m upfront to leverage BridGene’s chemoproteomics platform, dubbed IMTAC. The platform screens small ...
Clinical Trials Arena on MSN5d
Takeda and Protagonist report topline outcomes from trial of rusfertideTakeda and Protagonist Therapeutics have reported positive topline outcomes from their Phase III VERIFY trial of rusfertide ...
Takeda has returned to BridGene Biosciences ... to analyze interactions between small molecules and proteins in living cells. While most drugs form reversible bonds with targets, the history ...
LGND READ THE FULL LGND RESEARCH REPORT Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) reported 2024 financial and operational ...
Explore CAR-T responses and the challenges of durability in cancer treatment with innovative NKTR-255 interleukin-15 therapy.
Takeda and Protagonist Therapeutics have reported ... demonstrating a significant increase in clinical responders in the therapy arm, with 77% of these subjects achieving an absence of phlebotomy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback